Literature DB >> 10800416

Helping the urban poor stay with antiretroviral HIV drug therapy.

J D Bamberger1, J Unick, P Klein, M Fraser, M Chesney, M H Katz.   

Abstract

Recent studies have documented dramatic decreases in opportunistic infections, hospitalizations, and mortality among HIV-infected persons, owing primarily to the advent of highly active antiretroviral medications. Unfortunately, not all segments of the population living with HIV benefit equally from treatment. In San Francisco, only about 30% of the HIV-infected urban poor take combination highly active antiretroviral medications, as compared with 88% of HIV-infected gay men. Practitioners who care for the urban poor are reluctant to prescribe these medications, fearing inadequate or inconsistent adherence to the complicated medical regimen. Persons typically must take 2 to 15 pills at a time, 2 to 3 times a day. Some of the medications require refrigeration, which may not be available to the homeless poor. Most homeless persons do not have food available to them on a consistent schedule. Therefore, they may have difficulty adhering to instructions to take medications only on an empty stomach or with food. Lack of a safe place to store medications may be an issue for some. In addition, many urban poor live with drug, alcohol, or mental health problems, which can interfere with taking medications as prescribed. Inconsistent adherence to medication regimens has serious consequences. Patients do not benefit fully from treatments, and they will become resistant to the medications in their regimen as well as to other medications in the same classes as those in their regimen. Development of resistance has implications for the broader public health, because inadvertent transmission of multidrug-resistant strains of HIV has been demonstrated. Concern that the urban poor will not adhere to highly active antiretroviral medication regimens has led to debate on the role of clinicians and public health officials in determining who can comply with these regimens. Rather than define the characteristics that would predict adherence to these regimens, the San Francisco Department of Public Health created a program to support adherence among those who may have the greatest difficulty complying with complicated highly active antiretroviral medication regimens. The program, dubbed the Action Point Adherence Project, was conceived through a community planning process in preparation for a city-wide summit on HIV/AIDS that took place in January 1998. Action Point is funded by the city and the county of San Francisco. Now in its 10th month, the program continues to show promising evidence of improving clients' biological and social indicators.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10800416      PMCID: PMC1446238          DOI: 10.2105/ajph.90.5.699

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  8 in total

1.  Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors.

Authors:  F M Hecht; R M Grant; C J Petropoulos; B Dillon; M A Chesney; H Tian; N S Hellmann; N I Bandrapalli; L Digilio; B Branson; J O Kahn
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

Review 2.  Antiretroviral therapy for HIV infection: promises and problems.

Authors:  P A Volberding; S G Deeks
Journal:  JAMA       Date:  1998-05-06       Impact factor: 56.272

3.  Protease inhibitors in the homeless.

Authors:  D Bangsberg; J P Tulsky; F M Hecht; A R Moss
Journal:  JAMA       Date:  1997-07-02       Impact factor: 56.272

4.  Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

Authors:  D R Bangsberg; F M Hecht; E D Charlebois; A R Zolopa; M Holodniy; L Sheiner; J D Bamberger; M A Chesney; A Moss
Journal:  AIDS       Date:  2000-03-10       Impact factor: 4.177

5.  Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study.

Authors:  P P Sendi; H C Bucher; T Harr; B A Craig; M Schwietert; D Pfluger; A Gafni; M Battegay
Journal:  AIDS       Date:  1999-06-18       Impact factor: 4.177

6.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

7.  Combination antiretroviral therapy and recent declines in AIDS incidence and mortality.

Authors:  E Vittinghoff; S Scheer; P O'Malley; G Colfax; S D Holmberg; S P Buchbinder
Journal:  J Infect Dis       Date:  1999-03       Impact factor: 5.226

8.  HIV-1 RNA, CD4 cell count and the risk of progression to AIDS and death during treatment with HIV-1 reverse transcriptase inhibitors.

Authors:  S Staszewski; R DeMasi; A M Hill; D Dawson
Journal:  AIDS       Date:  1998-10-22       Impact factor: 4.177

  8 in total
  23 in total

1.  Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?

Authors:  B R Edlin; K H Seal; J Lorvick; A H Kral; D H Ciccarone; L D Moore; B Lo
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

2.  Directly observed versus self-administered antiretroviral therapies: preference of HIV-positive jailed inmates in San Francisco.

Authors:  Parya Saberi; Nikolai H Caswell; Ross Jamison; Milton Estes; Jacqueline P Tulsky
Journal:  J Urban Health       Date:  2012-10       Impact factor: 3.671

3.  Health status, health care use, medication use, and medication adherence among homeless and housed people living with HIV/AIDS.

Authors:  Daniel P Kidder; Richard J Wolitski; Michael L Campsmith; Glenn V Nakamura
Journal:  Am J Public Health       Date:  2007-10-30       Impact factor: 9.308

4.  Highly active antiretroviral therapy use and HIV transmission risk behaviors among individuals who are HIV infected and were recently released from jail.

Authors:  Kristen Clements-Nolle; Rani Marx; Michael Pendo; Eileen Loughran; Milton Estes; Mitchell Katz
Journal:  Am J Public Health       Date:  2008-02-28       Impact factor: 9.308

5.  The impact of unstable housing on emergency department use in a cohort of HIV-positive people in a Canadian setting.

Authors:  Surita Parashar; Keith Chan; David Milan; Eric Grafstein; Alexis K Palmer; Chelsey Rhodes; Julio S G Montaner; Robert S Hogg
Journal:  AIDS Care       Date:  2013-05-08

Review 6.  Prevention and treatment of hepatitis C in injection drug users.

Authors:  Brian R Edlin
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

Review 7.  Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users.

Authors:  Brian R Edlin; Thomas F Kresina; Daniel B Raymond; Michael R Carden; Marc N Gourevitch; Josiah D Rich; Laura W Cheever; Victoria A Cargill
Journal:  Clin Infect Dis       Date:  2005-04-15       Impact factor: 9.079

8.  Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.

Authors:  Evan Wood; Julio S G Montaner; Benita Yip; Mark W Tyndall; Martin T Schechter; Michael V O'Shaughnessy; Robert S Hogg
Journal:  CMAJ       Date:  2003-09-30       Impact factor: 8.262

9.  Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users.

Authors:  Frederick L Altice; Sandra Springer; Marta Buitrago; David P Hunt; Gerald H Friedland
Journal:  J Urban Health       Date:  2003-09       Impact factor: 3.671

10.  Hepatitis C virus infection in San Francisco's HIV-infected urban poor.

Authors:  Christopher S Hall; Edwin D Charlebois; Judith A Hahn; Andrew R Moss; David R Bangsberg
Journal:  J Gen Intern Med       Date:  2004-04       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.